𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effects of foreign bodies on development of urinary bladder tumors in rats treated with N-butyl-N-(4-hydroxybutyl) nitrosamine

✍ Scribed by Okajima, E. ;Hiramatsu, T. ;Motomiya, Y. ;Kondo, T. ;Hirao, Y.

Publisher
Springer
Year
1973
Tongue
English
Weight
482 KB
Volume
1
Category
Article
ISSN
0300-5623

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Effects of single chemotherapeutic agent
Effects of single chemotherapeutic agents on development of urinary bladder tumor induced by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in rats
✍ Babaya, K. ;Takahashi, S. ;Momose, H. ;Matsuki, H. ;Sasaki, K. ;Samma, S. ;Ozono πŸ“‚ Article πŸ“… 1987 πŸ› Springer 🌐 English βš– 537 KB

Chemotherapeutic agents were evaluated for effect on the development of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in male Wistar strain rats. Seven hundred and two rats were given 0.05% BBN in drinking water for 8 weeks. After BBN treatment, the animals were divi

Effect of sex hormones on development of
Effect of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine
✍ Okajima, E. ;Hiramatsu, T. ;Iriya, K. ;Ijuin, M. ;Matsushima, S. ;Yamada, K. πŸ“‚ Article πŸ“… 1975 πŸ› Springer 🌐 English βš– 662 KB

Male and female Wistar strain rats were given 0.05% N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in their drinking water for 6 weeks and then water without BBN for 18 weeks. Diethylstilbestrol and testosterone were implanted subcutaneously into both intact and gonadectomised animals before or after

Absence of FGFR3 mutations in urinary bl
Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(-4-hydroxybutyl)nitrosamine
✍ Claire Dunois-LardΓ©; Olivier Levrel; Aude Brams; Jean Paul Thiery; FranΓ§ois Radv πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 225 KB

Frequent activating mutations of FGFR3 (fibroblast growth factor receptor 3) are found in human urothelial cell carcinomas, particularly in superficial papillary tumours (in 74%-84% of pTaG1-G2), but not in carcinomas in situ (CIS) and at a low rate in invasive tumours (in 16%-21% of pT1-4). In mice